Pharmacokinetics and Toxicity of an Early Single Intravesical Instillation of Gemcitabine after Endoscopic Resection of Superficial Bladder Cancer

2007 
Background: The tolerability and plasma absorption of gemcitabine administered at 40 mg/ml after small and extensive endoscopic transurethral resection of bladder tumors (TURB) were evaluated. Patients and Methods: Nine patients with a history of recurrent superficial bladder cancer were eligible for a single immediate, post TURB, intravesical instillation of gemcitabine. The endoscopic resection was small in 5 patients and extensive in 4. The drug was administered at 40 mg/ml concentration (2000 mg in 50 ml saline) and held in the bladder for 1 hour. Plasma concentrations of gemcitabine and its metabolite (2',2'-difluorodeoxyuridine) were determined with a validated HPLC assay. The blood count and chemistry were performed one day and one week postoperatively. Results: Toxicity was comparable for patients who underwent small or large TURB. The most significant side-effects were grade 2 vomiting and a transient grade 2 leukopenia after small and large TURB respectively. Mean maximum gemcitabine concentrations were 1.47 Ig/ml in small TURB and 2.8 Ig/ml in large TURB. The highest peak concentration of 4.26 Ig/ml was found after extended bladder resection. Conclusion: A single, immediate postoperative, intravesical instillation of gemcitabine at high concentration is feasible with acceptable toxicity, and it may be considered as an option taking into account patient performance status, tumor characteristics and TURB extension. The natural history of superficial bladder cancer shows a high rate of recurrence, around 80%, and a lower rate of stage-grade progression (1). The dilemma linked to the high recurrence is not only related to the potential polychronotopic development of tumors beyond the urothelium. Soloway and Masters first demonstrated that tumor cells preferentially implant (from four to five fold) on a cauterized urothelial surface and that instillation of thiotepa or mitomycin significantly reduced the incidence of implantation (2). In order to be effective, the intravesical instillation should be started within one hour of tumor resection, since it dramatically decreases the incidence of bladder and urethral implantation (3). These results suggest that cell seeding is a significant factor which increases the recurrence rate after transurethral resection of bladder tumors (TURB) and that intravesical chemotherapy initiated immediately after TURB may reduce cell implantation. Other studies have focused on optimizing the intravesical
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    18
    References
    5
    Citations
    NaN
    KQI
    []